Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors

doi:10.19803/j.1672-8629.20220640

Abstract

Abstract: Objective To analyze the incidence of immune-related adverse reactions (irAEs) caused by immune checkpoint inhibitors (ICIs) in our hospital. Methods The clinical data of patients treated with ICIs in our hospital in 2021 was investigated via the hospital information system. The monitoring and occurrence of irAEs were analyzed. Results A total of 80 patients treated with ICIs were included, including 7 cases (8.75%) of injuries to immune-related thyroid function, 4 cases (5.00%) of checkpoint inhibitor pneumonitis (CIP), and 3 cases (3.75%) of immune-related cutaneous adverse events (ircAEs). Only 67.50% of the patients regularly had their thyroid function evaluated, 47.50% regularly had their adrenal cortical function assessed and 50.00% regularly had their heart function evaluated. Adverse reactions were poorly monitored or left unmonitored. Conclusion The incidence of irAEs that require clinical treatment in our hospital is consistent with what has been reported, and the treatment of patients with adverse reactions is generally acceptable. Oncology pharmacists can promote the standardized clinical use of ICIs by enhancing the monitoring and analysis of irAEs in hospitals.

Key words: immune checkpoint inhibitors, PD-1 monoclonal antibody, immune-related adverse reaction, tumors, hypothyroidism, pneumonia, immune-related cutaneous adverse reaction, adverse drug reaction

CLC Number:

R979.5
R994

ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun. Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.

References

[1] HAN Y, LIU D, LI L.PD-1/PD-L1 pathway: current researches in cancer[J]. Am J Cancer Res, 2020, 10(3): 727-742.
[2] ZHANG BL, CHENG XY, HUANG YQ, et al.The development of PD-1/PD-L1 targeted inhibitors[J]. Journal of Shenyang Pharmaceutical University(沈阳药科大学学报), 2022, 39(7): 887-892.
[3] National Medical Products Administration. Data search[EB/OL].[2022-02-26] https://www.nmpa.gov.cn/datasearch/home-index.html.
[4] US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5[EB/OL]. (2017-09-27)[2022-02-26]. http://guide.medlive.cn/guideline/18315.
[5] QING SM, WANG BC, GUO J, et al.Guidelines of Chinese Society of Clinical Oncology (CSCO) Management of immune checkpoint inhibitor-related toxicity(中国临床肿瘤学会免疫检查点抑制剂相关的毒性管理指南)[M]. Beijing: People's Medical Publishing House, 2021: 1-160.
[6] National Center for ADR Monitoring, China. Manual on Reporting and Monitoring of Adverse drug Reactions(药品不良反应报告和监测工作手册)[Z]. National Center for ADR Monitoring, China, 2012: 11.
[7] Guangdong Pharmaceutical Association.Guidelines for whole-process pharmaceutical care of immune checkpoint inhibitors[J]. Pharmacy Today(今日药学), 2020, 30(5): 289-306.
[8] MANUEL RC, JULIE RB, MARGARET KC, et al.Immune-related adverse events of checkpoint inhibitors[J]. Nature Reviews Disease Primers, 2020, 6(38): 34-54.
[9] LI L, LI G, RAO B, et al.Landscape of immune checkpoint inhibitor-related adverse events in Chinese population[J]. Scientific Reports, 2020, 10(1): 15567-15577.
[10] LI H, DING YL, ZHAI Q.Pay attention to the monitoring of adverse reactions of immune checkpoint inhibitors[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2022, 24(2): 57-60.
[11] LUONGO C, MORRA R, GAMBALE C, et al.Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy[J]. J Endocrinol Invest, 2021, 44(9): 1927-1933.
[12] WANG H, GUO X, ZHOU J, et al.Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis[J]. Thorac Cancer, 2020, 11(1): 191-197.
[13] WU JH, CHU XL, WANG LQ, et al.Epidemiological analysis of real-world immune checkpoint inhibitor-related pneumonitis in Chinese patients with lung cancer[J]. China Oncology(中国癌症杂志), 2022, 32(6): 469-477.
[14] ANDO H, SUZUKI K, YANAGIHARA T.Insights into potential pathogenesis and treatment options for immune-checkpoint inhibitor-related pneumonitis[J]. Biomedicines, 2021, 9(10): 1484-1495.
[15] ASADA M, MIKAMI T, NIIMURA T, et al.The risk factors associated with immune checkpoint inhibitor-related pneumonitis[J]. Oncology, 2021, 99(4): 256-259.
[16] WANG DY, SALEM JE, COHEN JV, et al.Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728.
[17] CHENG HX, ZHANG DJ, HAO F.Research progress in skin adverse reactions associated with immune checkpoint inhibitors [J/OL]. The Chinese Journal of Dermatovenereology(中国皮肤性病学杂志), 2023, 37(6):727-731.
[18] GEISLER AN, PHILLIPS GS, BARRIOS DM, et al.Immune checkpoint inhibitor-related dermatologic adverse events[J]. J Am Acad Dermatol, 2020, 83(5): 1255-1268.
[19] WANG F, QIN S, SUN X, et al.Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial[J]. J Hematol Oncol, 2020, 13(1): 47-56.
[20] JOHN AT, BRYAN JS, JULIE B, et al.Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(4): 387-405.
[21] YU CC, YUE XD, ZHANG XL, et al.Research progress in the application of PD-1/PD-L1 in tumor immunotherapy[J]. Journal of Jilin Normal University, Natural Science Edition(吉林师范大学学报自然科学版), 2022, 43(3): 112-118.